New drug IPH5301 targets tough cancers in first human trial
NCT ID NCT05143970
First seen Mar 27, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The drug aims to block a protein (CD73) that helps cancers hide from the immune system. The study first finds a safe dose of IPH5301 alone, then tests it combined with chemotherapy and trastuzumab in HER2-positive breast cancer patients. About 27 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Paoli Calmettes
RECRUITINGMarseille, France
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.